Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| LY2 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.0533 | uM | 7865.016 | 1.1341 | 1.1444 | 1.8047 | |
| LY2 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.267 | uM | 7865.016 | 1.2032 | 1.2159 | 1.8047 | |
| LY2 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 1.33 | uM | 7865.016 | 1.0312 | 1.0343 | 1.8047 | |
| LY2 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 6.67 | uM | 7865.016 | 1.0869 | 1.0945 | 1.8047 | |
| LY2 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 33.3 | uM | 7865.016 | 0.6678 | 0.5990 | 1.8047 | |
| LY2 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.0000853 | uM | 9536.019 | 0.9831 | 0.9783 | 1.5595 | |
| LY2 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.000427 | uM | 9536.019 | 1.0132 | 1.0168 | 1.5595 | |
| LY2 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.00213 | uM | 9536.019 | 0.9885 | 0.9852 | 1.5595 | |
| LY2 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.0107 | uM | 9536.019 | 0.9949 | 0.9935 | 1.5595 | |
| LY2 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.0533 | uM | 9536.019 | 1.0071 | 1.0091 | 1.5595 | |
| LY2 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.267 | uM | 9536.019 | 0.9643 | 0.9539 | 1.5595 | |
| LY2 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 1.33 | uM | 9536.019 | 0.9901 | 0.9872 | 1.5595 | |
| LY2 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 6.67 | uM | 9536.019 | 0.9097 | 0.8823 | 1.5595 | |
| LY2 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 33.3 | uM | 9536.019 | 0.5202 | 0.3153 | 1.5595 | |
| LY2 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.0000853 | uM | 10264.024 | 1.0288 | 1.0469 | 1.2223 | |
| LY2 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.000427 | uM | 10264.024 | 0.9833 | 0.9727 | 1.2223 | |
| LY2 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.00213 | uM | 10264.024 | 1.0004 | 1.0007 | 1.2223 | |
| LY2 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.0107 | uM | 10264.024 | 0.7777 | 0.6282 | 1.2223 | |
| LY2 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.0533 | uM | 10264.024 | 1.0237 | 1.0387 | 1.2223 | |
| LY2 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 0.267 | uM | 10264.024 | 0.9757 | 0.9601 | 1.2223 | |
| LY2 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 1.33 | uM | 10264.024 | 0.9447 | 0.9091 | 1.2223 | |
| LY2 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 6.67 | uM | 10264.024 | 0.9133 | 0.8570 | 1.2223 | |
| LY2 | HR+ | Luminal | Gefitinib | EGFR | ErbB | 33.3 | uM | 10264.024 | 0.6482 | 0.4027 | 1.2223 | |
| MB 157 | Unknown | Unknown | Gefitinib | EGFR | ErbB | 0.0000853 | uM | 9039.016 | 0.9591 | 0.8528 | 0.5468 | |
| MB 157 | Unknown | Unknown | Gefitinib | EGFR | ErbB | 0.000427 | uM | 9039.016 | 0.9159 | 0.7031 | 0.5468 |